Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for combined cervical dystonia has been reported in the published literature.
4 FDA-approved treatments are available for combined cervical dystonia, including ONABOTULINUMTOXINA (BOTOX COSMETIC, approved 1991), BOTULINUM TOXIN TYPE A (DYSPORT, approved 2009), and INCOBOTULINUMTOXINA (XEOMIN, approved 2010).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
No clinical trials have been registered for combined cervical dystonia.
51 publications have been identified in PubMed for combined cervical dystonia. Research spans Case Report / Case Series (27%), Clinical Trial Publication (25%), and Review / Meta-Analysis (22%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 | 27% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:24 PM UTC
European rare disease database
Common questions about combined cervical dystonia
DAXXIFY |
BOTULINUM TOXIN TYPE A |
— |
2022 |
Available |
XEOMIN | INCOBOTULINUMTOXINA | — | 2010 | Available |
DYSPORT | BOTULINUM TOXIN TYPE A | — | 2009 | Available |
MYOBLOC | RIMABOTULINUMTOXINB | — | 2000 | Available |
BOTOX COSMETIC | ONABOTULINUMTOXINA | — | 1991 | Available |
Gene therapy approaches for combined cervical dystonia have been reported in the published literature.
View trials for combined cervical dystonia
13 |
25% |
Research summaries | 11 | 22% |
Testing and diagnosis research | 4 | 8% |
Laboratory research | 4 | 8% |
Disease patterns and progression | 3 | 6% |
New treatment approaches | 2 | 4% |
Chen RK (2026). [PMID: 41786661](https://pubmed.ncbi.nlm.nih.gov/41786661/). *Movement disorders : official journal of the Movement Disorder Society*. [Gene Therapy / Novel Therapeutics]
Findley JL (2026). [PMID: 42194151](https://pubmed.ncbi.nlm.nih.gov/42194151/). *Children (Basel)*. [Review / Meta-Analysis]
Ottaviani D (2026). [PMID: 41978253](https://pubmed.ncbi.nlm.nih.gov/41978253/). *Am J Med Genet A*. [Case Report / Case Series]
Ledingham D (2026). [PMID: 42097654](https://pubmed.ncbi.nlm.nih.gov/42097654/). *BMJ Open*. [Clinical Trial Publication]
Xiaowei L (2026). [PMID: 41952138](https://pubmed.ncbi.nlm.nih.gov/41952138/). *BMC Pediatr*. [Case Report / Case Series]
Popescu C (2026). [PMID: 41780719](https://pubmed.ncbi.nlm.nih.gov/41780719/). *Eur J Med Genet*. [Case Report / Case Series]
Liu Y (2026). [PMID: 42065724](https://pubmed.ncbi.nlm.nih.gov/42065724/). *Childs Nerv Syst*. [Review / Meta-Analysis]
Pringsheim T (2026). [PMID: 41334637](https://pubmed.ncbi.nlm.nih.gov/41334637/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]
Poplawska-Domaszewicz K (2026). [PMID: 41553471](https://pubmed.ncbi.nlm.nih.gov/41553471/). *Journal of neural transmission (Vienna, Austria : 1996)*. [Clinical Trial Publication]
Banerjee S (2026). [PMID: 41265258](https://pubmed.ncbi.nlm.nih.gov/41265258/). *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. [Clinical Trial Publication]